Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PSMA CAR γδ T cells
- Development stage
- Unknown
- Lead developer
- Adicet Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Anti-PSMA CAR γδ T cells** represent an investigational allogeneic, off-the-shelf chimeric antigen receptor (CAR) cell therapy platform designed to target prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). Unlike conventional CAR-T therapies that utilize alpha-beta (αβ) T cells, this platform leverages gamma-delta (γδ) T cells (specifically the Vδ1 subset), which possess natural tissue-homing properties, MHC-independent tumor recognition, and a reduced risk of graft-versus-host disease (GvHD). The lead candidate of this platform, **ADI-212** developed by Adicet Bio, is engineered with a novel CAR binder targeting a conformational, membrane-distal epitope of the PSMA homodimer. ADI-212 is further enhanced with membrane-tethered interleukin-12 (mbIL-12) armoring to modulate the immunosuppressive tumor microenvironment and CRISPR/Cas9-mediated knockout of the MED12 gene to improve T-cell persistence and anti-tumor potency.
- Other names
- anti-PSMA CAR gamma delta T cellsanti-PSMA CAR-γδ T cellsPSMA-targeted CAR γδ T cellsPSMA-targeted CAR-gamma delta T cells
Beyond the preview
Go deeper on anti-PSMA CAR γδ T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PSMA CAR γδ T cells.